Zenith Labs Chapter 11
Executive SummaryReorganization plan filing deadline extended 120 days from Sept. 1 to Dec. 30. Generics company noted at the Aug. 29 hearing in Newark Federal Court that a further extension may be required. Court also extended Zenith's right to use collateral, subject to the requirement that monthly interest payments be made to the five-bank consortium. Zenith filed for Chapter 11 on May 4.
You may also be interested in...
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Genfit will delay unblinding of data from its nearly complete Phase III study of elafibranor to get insight from the FDA on statistical methods in order to optimize its NDA.
Revolution has just one drug in the clinic, but its focus on KRAS excited IPO investors. Also, Deciphera’s $175m offering leads recent follow-ons and Spruce raises $88m in venture capital.